Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer

Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Small-cell lung cancer (SCLC) is responsive to initial chemotherapy but becomes resistant to cytotoxic drugs. The aim of this study was...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	small cell lung cancer first-line chemotherapy second-line chemotherapy third-line chemotherapy retrospective study overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/15933dd49a0448d3aa1b054cf40628a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:15933dd49a0448d3aa1b054cf40628a1
record_format	dspace
spelling	oai:doaj.org-article:15933dd49a0448d3aa1b054cf40628a12021-12-02T06:20:59ZRetrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer1179-2728https://doaj.org/article/15933dd49a0448d3aa1b054cf40628a12016-04-01T00:00:00Zhttps://www.dovepress.com/retrospective-analysis-of-outcomes-and-prognostic-factors-of-chemother-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Small-cell lung cancer (SCLC) is responsive to initial chemotherapy but becomes resistant to cytotoxic drugs. The aim of this study was to evaluate what proportion of patients with SCLC had received the first- and further-line chemotherapy and which patients had benefited from chemotherapy. Methods: We retrospectively reviewed medical records of patients with SCLC who had been treated with the best supportive care alone and the first-, second-, or third-line chemotherapy at the Osaka Police Hospital from June 2007 until March 2015. Results: Among 145 patients diagnosed with SCLC and eligible for analysis, 118 patients received chemotherapy. We added five patients who initiated the second-line chemotherapy during the study period at our institution. Sixty-five and 31 patients received the second- and third-line chemotherapies, respectively. Multivariate logistic regression analysis detected age ≥75 years (odds ratio, 2.80; 95% confidence interval, 1.01–7.75; P=0.047) and European Clinical Oncology Group Performance Status (ECOG PS) 3–4 (14.3; 4.86–41.9; P<0.01) as factors disturbing the introduction of chemotherapy. Multivariate Cox hazard analyses also detected ECOG PS 2–4 (3.34; 2.00–5.58; P<0.01) as a factor decreasing overall survival after the first-line chemotherapy, and C-reactive protein level ≥1.0 mg/dL (2.67; 1.30–5.47; P<0.01) and progression-free survival after the first-line chemotherapy ≥6 months (2.85; 1.50–5.43; P<0.01) as factors influencing overall survival after the second-line chemotherapy. Conclusion: Approximately two-thirds and one-third of the patients who receive chemotherapy proceed to the second- and third-line chemotherapies, respectively. Several factors, such as age, ECOG PS, C-reactive protein level, and progression-free survival after previous treatment may be useful when considering the introduction of further-line chemotherapy. Keywords: small-cell lung cancer, first-line chemotherapy, second-line chemotherapy, third-line chemotherapy, retrospective study, overall survivalMinami SOgata YIhara SYamamoto SKomuta KDove Medical Pressarticlesmall cell lung cancerfirst-line chemotherapysecond-line chemotherapythird-line chemotherapyretrospective studyoverall survivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 35-44 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	small cell lung cancer first-line chemotherapy second-line chemotherapy third-line chemotherapy retrospective study overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	small cell lung cancer first-line chemotherapy second-line chemotherapy third-line chemotherapy retrospective study overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Minami S Ogata Y Ihara S Yamamoto S Komuta K Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
description	Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Small-cell lung cancer (SCLC) is responsive to initial chemotherapy but becomes resistant to cytotoxic drugs. The aim of this study was to evaluate what proportion of patients with SCLC had received the first- and further-line chemotherapy and which patients had benefited from chemotherapy. Methods: We retrospectively reviewed medical records of patients with SCLC who had been treated with the best supportive care alone and the first-, second-, or third-line chemotherapy at the Osaka Police Hospital from June 2007 until March 2015. Results: Among 145 patients diagnosed with SCLC and eligible for analysis, 118 patients received chemotherapy. We added five patients who initiated the second-line chemotherapy during the study period at our institution. Sixty-five and 31 patients received the second- and third-line chemotherapies, respectively. Multivariate logistic regression analysis detected age ≥75 years (odds ratio, 2.80; 95% confidence interval, 1.01–7.75; P=0.047) and European Clinical Oncology Group Performance Status (ECOG PS) 3–4 (14.3; 4.86–41.9; P<0.01) as factors disturbing the introduction of chemotherapy. Multivariate Cox hazard analyses also detected ECOG PS 2–4 (3.34; 2.00–5.58; P<0.01) as a factor decreasing overall survival after the first-line chemotherapy, and C-reactive protein level ≥1.0 mg/dL (2.67; 1.30–5.47; P<0.01) and progression-free survival after the first-line chemotherapy ≥6 months (2.85; 1.50–5.43; P<0.01) as factors influencing overall survival after the second-line chemotherapy. Conclusion: Approximately two-thirds and one-third of the patients who receive chemotherapy proceed to the second- and third-line chemotherapies, respectively. Several factors, such as age, ECOG PS, C-reactive protein level, and progression-free survival after previous treatment may be useful when considering the introduction of further-line chemotherapy. Keywords: small-cell lung cancer, first-line chemotherapy, second-line chemotherapy, third-line chemotherapy, retrospective study, overall survival
format	article
author	Minami S Ogata Y Ihara S Yamamoto S Komuta K
author_facet	Minami S Ogata Y Ihara S Yamamoto S Komuta K
author_sort	Minami S
title	Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
title_short	Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
title_full	Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
title_fullStr	Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
title_full_unstemmed	Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
title_sort	retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/15933dd49a0448d3aa1b054cf40628a1
work_keys_str_mv	AT minamis retrospectiveanalysisofoutcomesandprognosticfactorsofchemotherapyforsmallcelllungcancer AT ogatay retrospectiveanalysisofoutcomesandprognosticfactorsofchemotherapyforsmallcelllungcancer AT iharas retrospectiveanalysisofoutcomesandprognosticfactorsofchemotherapyforsmallcelllungcancer AT yamamotos retrospectiveanalysisofoutcomesandprognosticfactorsofchemotherapyforsmallcelllungcancer AT komutak retrospectiveanalysisofoutcomesandprognosticfactorsofchemotherapyforsmallcelllungcancer
_version_	1718399918246199296

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer

Ejemplares similares